Investigational Drug Details
| Drug ID: | D181 |
| Drug Name: | IMM-124E |
| Synonyms: | -- |
| Type: | Biological drug |
| DrugBank ID: | -- |
| DrugBank Description: | -- |
| PubChem ID: | -- |
| CasNo: | 1774337-30-2 |
| Repositioning for NAFLD: | No |
| SMILES: | -- |
| InChiKey: | -- |
| Molecular Weight: | -- |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | LPS |
| Therapeutic Category: | Gut microbiome modulator |
| Clinical Trial Progress: | Phase 2 completed (NCT02316717: the peptide AWRK6 ameliorates MAFLD by improving lipid and glucose metabolism homeostasis, and it is mediated by the PI3K/AKT/AMPK/ACC signaling pathway. Thus, AWRK6 has a potential in preventing MAFLD.) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0559 | NCT03042767 | Phase 2 | Not recruiting | No Results Available | 02/02/2017 | 12 December 2020 | Details |
| L0620 | NCT02316717 | Phase 2 | Not recruiting | Has Results | 06/11/2014 | 12 December 2020 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|